Compare Quest Diagnostics Inc (DGX) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Levi Strauss & Co. — how do they compare? Quest Diagnostics Inc trades at $237.86 (market cap $26.21B), while Levi Strauss & Co. trades at $22.53 (market cap $8.75B). The key difference: Quest Diagnostics Inc is far larger — about 3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| DGX | LEVI | |
|---|---|---|
Market Cap | $26.21B | $8.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $25.53 |
52-Week Low | $173.49 | $17.92 |
Enterprise Value | $31.97B | $10.07B |
Dividend Yield | 1.45% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Levi Strauss (LEVI) trades at $22.57, down 4.32% amid a recent cybersecurity breach disclosure. The stock maintains strong fundamentals with a 9.66% net margin and 29.31% ROE, supported by three consecutive quarterly earnings beats. Technical indicators show mixed signals with bearish moving averages but oversold RSI conditions. Analyst consensus remains strongly bullish with a $27.88 price target representing 23.5% upside potential.
Despite near-term cybersecurity concerns, Levi's demonstrates robust DTC growth and digital transformation success. The company's raised 2026 outlook and dividend increase signal confidence, though execution risks and tariff pressures warrant monitoring. Current valuation at 16.24 P/E offers reasonable entry for long-term investors seeking exposure to the iconic brand's turnaround story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
